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INTRODUCTION 
 
Squamous cell carcinoma (SCC) of the mouth constitutes the sixth 
most common cancer worldwide but the third most common in developing 
countries.1 There is evidence of an increase in incidence rate and mortality as 
a result of this disease in recent years, particularly in young adults in Central 
Europe.2 Despite advances in treatment modalities, the prognosis of this 
cancer is still very poor and has not changed over the past few decades. 
Biological phenotypes of cancer greatly affect the clinical outcomes of 
patients with the disease. If such biological characteristics of cancer could be 
predicted before treatment, it would be possible to select more effective and 
suitable treatment for each cancer. Recent studies have clarified that a variety 
of molecular events play extremely important roles in not only tumor 
development but also tumor progression. Consequently, special attention has 
turned to molecular markers as a possible means for obtaining useful 
information to predict aggressive phenotypes of tumors.3 
Since the current TNM staging system is also inadequate to accurately 
classify the patients of oral SCC in terms of prognosis, it is important to look 
for new biological prognostic markers that might add information about the 
aggressiveness of the tumors and treatment response. So, the interest lies in 
studying the molecular markers involved in cell cycle regulation of tumor cells 
p53 and cyclin D1. The p53 tumor-suppressor gene regulates cell cycle 
progression through induction of apoptosis at the G1/S checkpoint.4,5 
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Immunohistochemical p53 protein expression is based on the prolonged  
half-life of the mutant protein compared to the wild-type.6 Cyclin D1 plays a 
central role in the G1/S cell cycle transition and responses to cytotoxic 
stimuli.7, 8  We were also interested in the expression of CD44 molecule that 
has been correlated to carcinogenesis and aggressive biological behavior of 
several malignant tumors. CD44 is a polymorphic family of cell surface 
proteoglycans and glycoproteins implicated in cell-cell and cell-matrix 
adhesion interactions, lymphocyte activation and homing, cell migration and 
tumor metastasis. 
 In view of the prospective impact of multiple molecular marker 
accumulation on tumor progression, multiple-marker testing could provide us 
with more useful information for our definition of the biological behavior than 
single marker expression. So, in our study we have analyzed the expression 
of cell cycle regulatory proteins p53 and cyclin D1, cell adhesion molecule 
CD44 using immunohistochemistry in oral squamous cell carcinoma and its 
variant verrucous carcinoma. We also studied the impact of expression of 
these markers on clinico-pathological features like histological grading of the 
tumor and cervical node metastasis. 
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AIM OF THE STUDY 
 
• To study the abnormal expression of cell cycle regulatory proteins 
particularly p53 and Cyclin D1 in oral squamous cell carcinoma using 
immunohistochemistry. 
• To study the expression of cell adhesion molecule CD44 in oral 
squamous cell carcinoma using immunohistochemistry. 
• To compare the expression of these markers in different histological 
grades of oral squamous cell carcinoma. 
• To study the expression of these markers in verrucous carcinoma. 
• To study the role played by the three molecular markers p53, cyclin D1 
& CD44 in tumor grade and cervical node metastases. 
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NEED FOR THE STUDY 
 
Oral SCC, an aggressive epithelial malignancy is posing a major threat 
to public health worldwide. In global terms oral cancer is the sixth most 
common malignancy associated with great morbidity and mortality.  
Despite numerous advances in treatment utilizing the most recent 
protocols for surgery, radiation and chemotherapy, the cure rates and survival 
rates have not improved during the last 40 years, 5 year survival rate 
remaining approximately 55%. And also the current TNM system is 
inadequate to accurately classify the patients in terms of prognosis.  
Thus with recently developed molecular tools the interest lies in the 
study of distribution of the molecular markers p53, cyclin D1 and CD44 in oral 
squamous cell carcinoma and their association with histopathological grading 
and cervical lymph node metastasis of this tumor. This will help to identify the 
subgroup of patients with poor prognosis who may need intense treatment 
strategies and also to guide treatment options thereby improving the survival 
rates in these patients. 
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REVIEW OF LITERATURE 
INCIDENCE OF ORAL SCC: 
More than 90% of malignant neoplasms of the oral cavity and 
oropharynx are squamous cell carcinomas of the lining mucosa with relatively 
rare neoplasms arising in minor salivary glands and soft tissues.(WHO). Oral 
squamous cell carcinoma (OSCC) is the most common cancer of the head 
and neck region and accounts for over 300,000 new cancer cases worldwide 
every year.15 In the US, incidence of new oral cancer estimated in the year 
2009 is 35,720 as compared to the incidence for all cancers that is estimated 
to be 1,479,350. It is the ninth most common cancer among men in the US. 
Death rates are declining from 5.61 and 2 per 100,000 in males and females 
respectively in the year 1990 to 3.84 and 1.4 per 100,000 in the year 2005 
amounting to a decrease of 31%. Although the death rates are declining the 
five-year overall survival rates remain around 50% over the past several 
decades (53% in 1974 to 60% in 2004). 16, 17 India has one of the highest 
incidences of Oral cancer in the world. 18 The high incidence of oral cancer 
and oral pre-cancerous lesions in India has long been linked with the habit of 
betel quid chewing incorporating tobacco. Oral cancer ranks number one 
among men and number three among women in India. Oral cancer 
constitutes 12% of all cancers in men and 8% of all cancers among women.19 
Annual incidence rate is estimated to be 64,460. However total number of 
cases at any given time will be 2.5 to 3 times higher than this number. It is 
unfortunate that so far no proper epidemiological data on this disease is 
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available in India. Information currently available is mostly on the basis of 
crude incidence rate available from three metropolitan cities covered under 
National cancer registry project.    
AGE DISTRIBUTION: 
Oral carcinoma is largely a disease of the elderly and the incidence 
rises sharply with age. Seventy percent of the cancer develops between  
55 and 77 years of age.  
Although primarily a disease of the middle and older age groups, a 
younger patient population presenting with oral cancers has increased 
alarmingly in the recent years. In this younger group, the etiological factors 
associated with oral cancer development remain poorly defined with proposed 
familial, occupational, immune deficiency and viral linked factors most often 
favoured. 
GENDER DISTRIBUTION: 
Men are affected more often than women because of heavier 
indulgence in both tobacco and alcohol habits in most countries; In India, the 
highest rates of intraoral cancer may be found in women who chew tobacco 
heavily.  
ETIOLOGY OF OSCC: 
Epidemiologic data established tobacco and alcohol use as the major 
causes of oral cancer.20-22 Oral cancer risk is almost 10 times greater in 
individuals who smoke and drink than who do not and almost 100 times 
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greater in persons who smoke and drink heavily. A substantial percentage of 
the people with these risk behaviours, however, do not develop cancer. Other 
OSCC risk factors are betel quid chewing and possibly marijuana use.23, 24 
These factors, and tobacco and alcohol use, also increase the risk of oral 
IEN.25 Although human papilloma virus (HPV) infection has been hypothesized 
for decades to play a role in the etiology of oral neoplasia, various studies 
have found different and contradictory frequencies of HPV DNA detection in 
oral mucosal lesions.26, 27 A population-based study of 900,000 persons 
indicated that HPV infection is less a factor in developing OSCC than in 
developing nasopharyngeal or laryngeal cancer.28 Furthermore, recent data 
from the largest sample size yet analyzed could not establish a link between 
HPV infection and the development of either regular IEN or more-aggressive 
verrucous oral IEN.29 Nevertheless, HPV may be involved in some patients 
who develop oral neoplasia, for example, in a subset of OSCC patients 
without tobacco or alcohol risk factors. In addition, immune deficiency as seen 
in patients receiving immune suppressive therapy for organ transplant can 
play a role in development of oral cancers.30 In contrast patients infected with 
HIV are not predisposed to oral squamous cell carcinoma.30  
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MOLECULAR PATHOGENESIS OF OSCC: 
ORAL CARCINOGENESIS-A MULTISTEP PROCESS: 
OSCC evolves through a multistep process of genetic, epigenetic, and 
metabolic changes resulting from exposure to the carcinogens discussed 
above.20, 31 The clinical natural history of OSCC development usually involves 
normal oral mucosa changing to oral leukoplakia (or IEN) changing to OSCC. 
Illustrated by molecular progression models (Fig 1), oral IEN is a pathologically 
discernable intermediate state between normal epithelium and invasive cancer. 
Clinically relevant IEN has genetic or epigenetic alterations, loss of cellular 
control, phenotypic characteristics overlapping those of invasive cancer, and a 
substantial risk of biologically aggressive cancer.32 Accumulating molecular or 
genetic and epigenetic, alterations within oral carcinogenesis include alterations 
of tumor suppressor genes such as FHIT (loss of heterozygosity [LOH] at 
chromosomal region 3p14), p16 (promoter hypermethylation or LOH at 9p21), 
and p53 (inactivation/loss or mutation at 17p), cyclin D1 overexpression (and 
gene amplification at 11q13), and telomerase activation.20, 31 Tobacco may 
cause oral cancer, in part, via effects on p53 and the chromosomal region 3p. 
Altered p53 expression is associated with increased genomic instability  
(eg, aneuploidy) in oral IEN and may drive the acceleration in the rate of genetic 
alterations during oral tumorigenesis.33 The overexpressions of cyclooxygenase-
2 (COX-2) and phospho-epidermal growth factor receptor (pEGFR) also are 
important events in oral carcinogenesis. 
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 Figure 1: Molecular (genetic & epigenetic) progression model of 
multistep oral carcinogenesis. The white central steps of the figure 
represent the progression of oral intraepithelial neoplasia from leukoplakia 
(white patches) to erythroplakia (red patches), which can precede cancer. 
This process involves activation of the epidermal growth factor receptor 
(EGFR) and related downstream events (eg, involving cyclooxygenase-2 
[COX-2] and cyclin D1) leading to dysregulated proliferation, increasing 
frequency of mutations causing genomic instability (and vice versa) and 
invasion. (LOH-loss of heterozygosity; RARβ-retinoic acid receptor-beta). 
A number of studies have revealed the pivotal role played by proto-
oncogenes and tumour suppressor genes in cell cycle regulation and apoptosis, 
indicating their aberrant expression during the course of evolution of various 
human cancers. The Rb pathway and the p53 pathway are two important, 
interconnected biochemical pathways frequently perturbed in human cancer. It 
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has been reported that more than 90% of oral tumours had at least one 
abnormality affecting either Rb or cyclin D1 or p16 and the data suggest that this 
pathway is a near universal target in oral carcinogenesis. After activation by cyclin 
D1, CDK4 or CDK6 is able to phosphorylate the Rb protein, leading to its 
functional inactivation and release of transcription factors necessary for entry into 
S phase and cell cycle progression.  
p53 is reported to play a key role to ensure genomic integrity. In order to 
facilitate this, apoptosis should be tightly coupled to cell cycle checkpoints. In 
response to a variety of types of DNA damage, the p53 tumour suppressor gene 
product is activated and regulates a number of downstream cellular processes 
such as cell cycle arrest, apoptosis and DNA repair.  In our study we have 
investigated the expression of Rb pathway protein, Cyclin D1 and p53 pathway 
protein, p53 in oral SCC. 
 
Figure 2: Flow diagram showing the role of major components of p53 
and Rb pathways in cell cycle regulation. 
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CELL CYCLE DYSREGULATION IN CANCER: 
Dysregulation of the cell cycle machinery is a fundamental hallmark of 
cancer progression.34 The cellular programs of proliferation, differentiation, 
senescence, and apoptosis are intimately linked to the cell cycle regulatory 
machinery. Many of the molecular alterations that cause abnormal biologic 
behavior of cancer cells are based on aberrations of cell cycle regulation.  
For example, escape from dependence on mitogens or induction of resistance to 
anti-mitogens, tolerance to DNA damage, apoptosis resistance, and progression 
of cells with activated oncogenes and/or inactivated tumor suppressor genes 
through multiple checkpoints resulting in increased genomic instability—all affect 
and/or are affected by cell cycle regulatory proteins.34  
The cyclins and cyclin-dependent kinases (CDKs) form the core of cell 
cycle regulation.35 Expression of cyclins is cell cycle phase-dependent and 
 is regulated transcriptionally, post-transcriptionally, and translationally/ 
posttranslationally. The cyclin family members interact with CDKs, and these 
complexes are required to pass through specific phases of the cell cycle.  
D-type cyclins interact with CDK4 and CDK6 and are necessary for G0/G1 
transition. Cyclin E binds to CDK2 and mediates S phase entry. The cyclin 
A/CDK2 complex regulates passage through the S-phase. Later, in 
conjunction with CDC 2, cyclin A also induces the G2 phase of the cell cycle. 
Cyclin B1 and CDC2 trigger the molecular events associated with mitosis.34 
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CYCLIN D1 AND MITOGEN-ACTIVATED CELL CYCLE PROGRESSION: 
D-type cyclins represent a link between upstream mitogenic stimuli and 
regulation of pRB function.36 Human cyclin D1 was first isolated in human 
parathyroid adenomas as a gene rearranged by translocation to the parathyroid 
hormone locus at 11q13.37 Two other human D-type cyclin genes, cyclins D2 and 
D3, have also been cloned. All three human D-type cyclin genes encode 33-34-
kDa proteins that share an average of 57% identity over the entire coding region 
and 78% in the cyclin box, the region of the cyclins that interacts with CDKs. There 
is compelling evidence for a role of cyclin D1 in G1 phase progression in the cell 
cycle. Microinjection of cyclin D1 antibody or antisense cyclin D1 blocks cells from 
entering the S phase.38 Overexpression of cyclin D1 accelerates progression 
through the G1 phase of the cell cycle and reduces the requirement of the cell for 
mitogens.39 D-type cyclins and their catalytic partners, CDK4 and CDK6, play an 
important role in modulating the response to extracellular stimuli and are believed 
to be essential for passage through the G1 phase. 36 
Cyclin D1's role as an oncogene has been established by its ability to 
cooperate with RAS or complement a defective adenoviral E1a oncogene in cell 
transformation assays.40-44 Overexpression of cyclin D1 has been reported in a 
variety of human tumors, including breast carcinomas, mantle cell lymphomas, and 
squamous cell carcinomas derived from the oral cavity, larynx, and esophagus as 
well as from other sites. 45 The mechanisms underlying cyclin D1 overexpression in 
cancer include gene amplification, chromosomal translocation, and mitogenic 
stimulation of gene transcription.40 The abrogation of mitogenic pathways that might 
12 
 
lead to overexpression of cyclin D1 during oral carcinogenesis has been reviewed 
extensively elsewhere.46 In the majority of primary oral cancers and cell lines, cyclin 
D1 overexpression appears independent of p16INK4a inactivation.47 The role of 
cyclins D2 and D3 in oral carcinogenesis is poorly understood. Expression of 
antisense cyclin D1 induces apoptosis and tumor shrinkage in squamous cell 
carcinomas.48 Moreover, cyclin D1 overexpression has also been linked to 
increased risk of occult metastases and poor prognosis in oral cancer patients.49 
 
Figure 3: Mitogen Signals. Mitogen-activated G1 transition to the S 
phase. Mitogen stimulation leads to cyclin D1 synthesis. Together with its catalytic 
partners CDK4 and CDK6, cyclin D1 accelerates G1 progression by 
phosphorylating pRB. It is now apparent that improved treatment for OCSCC 
hinges on understanding the underlying dysregulation of the molecular processes 
in OCSCC. 
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THE P53 PATHWAY AND GENOMIC DAMAGE: 
Genomic damage and other cellular stress signals elicit a cellular 
response pathway that delays or prevents cell division. The p53 tumor 
suppressor protein acts as a master regulator of this pathway and induces 
cell cycle inhibition and/or apoptosis following DNA damage. Under normal 
cellular growth conditions, p53 has a short half life, and the cellular steady-
state levels are very low. When treated with a variety of DNA-damaging 
agents, such as ultraviolet or ionizing radiation and certain chemotherapeutic 
drugs, normal cells respond by a rapid, non-transcriptional induction of p53 as 
well as posttranslational modification including phosphorylation through the 
ATM/ATR and DNA PK family of protein kinases.50 Depending on the 
circumstances, this induction of p53 causes cell cycle arrest or apoptotic cell 
death.51 The p53-mediated induction of apoptosis is the subject of intense 
research and involves both transcriptional and non-transcriptional 
mechanisms.52-57 
The induction of G1 growth arrest by p53 is mediated by the 
transcriptional activity of p53. Expression of p21WAF1/CIP1 mRNA and 
protein is strongly induced by p53 under these conditions, and p21WAF1/CIP1 
can itself inhibit cell proliferation upon introduction into cultured cells.58, 59 The ability 
of p21WAF1/CIP1 to inhibit many different cyclin/CDK complexes suggests that 
p21WAF1/CIP1 has a broad effect on cell cycle progression.60 This p53- mediated 
cell cycle arrest in response to DNA damage is thought to prevent the perpetuation 
of genomic mutations by allowing a cell to repair DNA damage before it undergoes 
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a new round of DNA replication. Thus, p53 is involved in maintaining the integrity of 
the genome and has been referred to as the 'guardian of the human genome'.61 
Moreover, it is widely believed that the common absence of functional p53 in human 
tumors contributes to genomic instability, which is a hallmark of human tumors and 
pathologically manifested as nuclear pleomorphism. 
THE P53 PATHWAY AND ABERRANT CELL PHYSIOLOGY: 
The p53 and pRB tumor suppressor pathways are linked in many ways.  
On one hand, the ability of p53 to induce G1 growth arrest critically depends on the 
integrity of pRB.34 Conversely, abnormalities in the pRB pathway are sensed by 
p53. Normally, E2F activity is tightly regulated by pRB. Dysregulated E2F activity, 
for example, caused by a mutation in the pRB pathway triggers apoptosis that is at 
least in part p53-mediated. Loss of p53 function is well-documented in oral cancers, 
and p53 mutations have been reported in over 60% of oral squamous cell 
carcinomas. 62 Mutation of p53 frequently induces a stabilization of the mutated 
protein. While little p53 is detected in normal oral epithelia and low-grade 
leukoplakias (mild to moderate dysplasia), p53 accumulation (indicative of p53 
mutation) is more frequent in high-grade leukoplakias (severe dysplasia). 
Accumulation of the mutated p53 in malignant oral epithelium has been 
demonstrated by several immunohistochemical studies.63, 64 Elevated p53 in oral 
cancers correlates with heavy smoking but not with patient age.65-67 However, 
younger patients demonstrate p53 accumulation earlier during malignant 
progression (Castle et al., 1999). Mutant p53 has been investigated as both a 
diagnostic and a therapeutic adjunct.68-71 Last, p53 has been used as a prognostic 
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marker for current head and neck cancer therapy.72-75 These studies mostly 
correlate the mutation of p53 with an unfavorable response to chemotherapy and 
radiation. However, the heterogeneity of p53 mutations renders the design of simple 
assays for this biomarker exceedingly difficult. 76 
 
 
Figure 4: p53 and cell cycle regulation. Metabolic stresses (such as 
anoxia) and DNA damage lead to elevated p53 activity, resulting in cell cycle 
arrest and apoptosis. 
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CD44: 
Besides alterations in their cell-cycle control mechanisms, tumour cells 
must have the ability to invade adjacent and distant tissues. Although the 
phenotypic changes that increase the capacity of tumour cells for invasion are 
not well known 9, alterations in the expression of intercellular adhesion 
molecules on the tumour cell surface have been implicated. 10-12  
CD44 is the major human cell surface receptor for hyaluronate and 
functions in a diverse range of physiological processes. CD44 may play a role in 
stimulating in vivo aggressiveness of tumors through hyaluronate-rich stroma.77 
Expression of CD44 has been described to correlate with metastasis formation in 
various tumors, although evidence in oral cavity cancers is inconclusive.  
The purpose of the present study was to examine CD44 expression in oral cavity 
cancers and to investigate its correlation with histological grading and cervical 
node metastasis along with cell cycle regulators p53 and Cyclin D1. 
The CD44 glycoproteins are well characterized members of the 
hyaluronate receptor family of cell adhesion molecules. This group is defined 
functionally, rather than structurally, and binds to ligands of the extracellular 
matrix (ECM). The major ligand is hyaluronate, which is an abundant 
extracellular polysaccharide found in mammalian ECM, but CD44 appears to 
have many varied functions dependant on the extracellular structure of the 
protein, which can be produced in a myriad of isoforms. The wide range of 
functional proteins is produced from a single gene by both alternative splicing 
and post-translational modification.78 
17 
 
 Figure 5: CD44 protein structure. The standard isoform binds its 
principal ligand, hyaluronic acid at the N-terminal, distal extracellular domain. 
The inclusion of combinations of the variant exons (v1–10) within the 
extracellular domain can alter the binding affinity for hyaluronic acid and 
confer interaction with alternative ligands. The molecule interacts with the 
cytoskeleton through the binding of ankyrin and the ERM family (ezrin, radixin, 
moesin) to the cytoplasmic domain. 
CD44s, as its name implies, was first isolated on hemopoietic cells.79  
It has since been found on a wide range of tissues including the central 
nervous system, lung, epidermis, liver, and pancreas.12, 80, 81  
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PHYSIOLOGICAL ROLES OF CD44: 
The varied structure and distribution of CD44 suggests that the 
molecule has a variety of functions. Known functions of CD44 are: 
• Cellular adhesion (aggregation and migration) 
• Hyaluronate degradation 82 
• Lymphocyte activation 83-87 
• Lymph node homing 79, 88 
• Myelopoiesis and lymphopoiesis 89-91 
• Angiogenesis 92 
• Release of cytokines 93. 
ROLE OF CD44 IN TUMORIGENESIS AND METASTASIS: 
CD44 functions are principally dependant on cellular adhesion in one 
setting or another.94 This adhesion can lead to interaction between two 
different cells or between a cell and its pericellular matrix. There are many 
potential theories about the possible mechanisms involved with respect to the 
role of CD44 in tumorigenesis. CD44 expression is associated with a high 
rate of cell division. The proliferation status of tumour cells increases when 
cultured on anti-v6 antibody coated plates. CD44v6 on the cell surface is 
thought to crosslink with other CD44v6 molecules, initiating signals of growth 
promoting activity.91 Interactions between CD44 and its ligands might induce 
the tumour cells to produce autocrine growth factors. These factors might be 
critical for tumour growth. The functions of CD44 beyond cellular adhesion  
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require the transmission of intracellular signals. Some of these signals are 
thought to occur via the cytoskeleton and might enable CD44 to signal to both 
the locomotory92, 95 and mitogenic machinery of the cell.92 
Metastatic spread requires a series of interactions between the tumour 
cells and the surrounding extracellular matrix and nontumour cells. These 
interactions will depend on cell surface determinants such as extracellular 
receptors for matrix and basal lamina, surface bound proteolytic enzymes, 
cell adhesion molecules, growth factors, and growth factor receptors.96  
The metastasising tumour cell copies the same mechanisms of normal 
cellular migration. From the review of the physiological functions of CD44 it 
can be seen that CD44 can function as a cell surface determinant for several 
of the roles required for metastatic spread to occur. The theoretical steps of 
the metastatic process are known as the metastatic cascade.97, 98 and they 
consist of: (1) loss of contact with the surrounding tumour cells or 
neighbouring cells; (2) breakthrough of the basement membrane and penetration 
of vessel walls; (3) survival of shearing forces in the bloodstream/lymph stream; 
(4) adhesion and penetration through the vessel walls; (5) expansion into foreign 
tissue; (6) induction of vascularisation of tumour. 
For a tumour cell to lose contact with neighbouring tumour cells, its 
adhesive properties must change. Changing the cell’s CD44 profile could 
certainly achieve this. Increased expression of CD44 can enhance binding to 
hyaluronate and a pericellular matrix of hyaluronate might decrease the 
affinity of a cell for surrounding hyaluronate deficient cells by interfering with 
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adhesion processes, thus leading to detachment. This increased mobility is 
thought to be initiated by CD44 because it is linked to the cell’s 
cytoskeleton.92, 95 A CD44– ligand complex could mediate the mechanical 
force and transmit intracellular locomotory signals via the cytoskeleton. This 
response could lead to the cells enhanced movement along hyaluronate rich 
surfaces.99 As previously discussed, CD44 has the ability to take up and 
degrade hyaluronate,82 and this property could allow tumour cells to escape 
entrapment within hyaluronate rich environments. 
Migration of any cell to the vascular or lymphatic system requires both 
cell adhesion molecules and cell surface enzymes. The ability of CD44 to 
degrade hyaluronate could also be used by the tumour cell to assist in its path 
through the basement membrane and vessel wall. Tumour cells that 
metastasize by way of the lymphatic system are thought to imitate 
lymphocytes, entering peripheral lymphatics and travelling to the draining 
lymph nodes.86 Variants of CD44 are involved in the activation of lymphocytes 
and the release of cytokines.93 CD44s is required for lymphocyte homing 
within the lymphatics to the high endothelial venules within lymph nodes.79, 88 
In a lymphoma animal model, CD44 monoclonal antibodies did not inhibit 
spleen metastases developing, whereas they did affect the incidence of 
metastases to the lymph nodes.100 These observations imply that special 
variant isoforms of CD44 may be involved in the specific homing of  
tumour cells. 
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THE CONCEPT OF SECOND PRIMARY TUMORS IN UPPER 
AERODIGESTIVE TRACTS: 
Local treatment of oral IEN (particularly aggressive IEN) has produced 
dismal results with respect to oral cancer prevention. A major probable cause 
of these poor results is the field process of oral carcinogenesis. The concept 
of ‘‘field cancerization’’ was introduced by Slaughter et al 101 more than  
50 years ago and was based on the exposure of wide fields of epithelial 
surface within the aerodigestive tract to carcinogens such as tobacco and 
alcohol, thus increasing the risk of cancer development. According to the field 
cancerization model, multiple oral cancers arise from separate or independent 
cell clones. However, genetic analyses indicate that subsequent cancers 
distant from the original tumor also may derive from the spread of the original 
clone.102 It is hypothesized that an oral epithelial stem cell initially acquires a 
genetic alteration and parents a clonal unit consisting of itself and daughter 
cells with the same DNA alteration. Next, a lesion patch progresses into an 
expanding field as a result of additional genetic alterations. This mucosal field 
replaces the normal epithelium and may be visible as oral IEN. Ultimately, 
clonal selection leads to the development of carcinoma within this field of IEN 
cells. This model entails the important clinical implication that fields often 
remaining after surgery of the primary IEN/tumor may lead to new cancers, 
presently designated as second primary tumors (SPTs) or local recurrences. 
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GENERAL PATHOLOGIC FEATURES OF ORAL SCC:  
Oral epithelial dysplasia: Features characteristic of oral epithelial 
dyaplasia are the classic cytological abnormalities associated with most 
epithelial atypias. 
Microscopic features of oral epithelial dysplasia: 
• An increased nuclear cytoplasmic ratio. 
• Sharp angled rete processes. 
• Loss of cell polarity. 
• Cellular pleomorphism. 
• Nuclear pleomorphism. 
• Enlarged nucleoli. 
• Reduction of cellular cohesion. 
• Individual spinous layer cell keratinization. 
• Increased number of mitotic figures. 
• Presence of mitotic figures in the superficial half of the epithelium. 
• Basal cell layer hyperplasia. 
• Loss of basal cell polarity. 
CARCINOMA IN SITU: 
The diagnosis of carcinoma in situ of the oral mucosa is based on rigid 
histological criteria. Classically a carcinoma in situ sample should show all the 
atypical cytologic criteria necessary for a malignant diagnosis, but these 
atypical changes must be confined to the epithelial layer. With carcinoma in 
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situ, one must identify an intact basement membrane and top to bottom 
epithelial dysplasia. Lesions that are diagnosed as carcinoma in situ may 
appear red, white, blue or black clinically and on occasion they may present 
as a tumor mass. 
PATHOLOGICAL FEATURES OF INVASIVE SCC: 
GROSS:  
Grossly squamous cell carcinoma of the oral cavity can present as an 
ulcer, an alteration of mucosal color or a tumor mass. Ulcerative lesions 
usually have a crateriform appearance with roled elevated borders that are 
firm because of the infiltration of tumor along the margins. The cut section 
usually has a grey white glistening appearance with little tendency to bulge 
beyond the cut margins. 
MICROSCOPY:  
A proliferation of sheets, nests, chords and neoplastic islands of 
epithelium that penetrate into the supporting connecting tissue lamina propria 
and submucosa characterize squamous cell carcinoma. The neoplasm is 
usually identified histologically as been well differentiated, moderately 
differentiated, poorly differentiated or undifferentiated (non-keratinizing). 
Tumors are generally graded as grades I to IV, in which grade I tumors 
closely resemble the tissue of origin and grade IV tumors demonstrate very 
few features that resemble tissue of squamous epithelial origin.  
The neoplastic cells of well differentiated squamous carcinomas bear a 
striking similarity to the cells of normal squamous epithelium. The cells are 
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generally large with vescicular to oval nuclei and eosinophillic cytoplasm, 
intracellular bridging is usually easily discernible, and the degree of nuclear 
hyperchromatism and bizarre mitotic activity is minimal. Keratin pearl 
formation is usually quite prominent in well differentiated squamous cell 
carcinoma, and individual cell keratinization tends to be a hallmark of this 
disease. As the tumor becomes less differentiated, although the tumor cells 
resemble normal squamous epithelial cells, hyperchromatism, pleomorphism 
and loss of attachment of cells are more prominent. The frequency of atypical 
mitosis is increased and the frequency of individual cell keratinization and 
keratin pearl formation is decreased. In poorly differentiated squamous cell 
carcinomas, there is very little evidence that the tumor is of squamous origin 
and there is significant pleomorphism and atypical mitosis. Undifferentiated 
squamous cell carcinomas have little if any resemblance to a neoplasm of 
squamous epithelium with the cells resemling histiocytes, atypical 
lymphocytes or spindle fibroblasts. Electron microscopic evaluation and 
immunohistochemical staining for keratin may be the only method of 
documenting that the tumor is of squamous epithelial origin. 
VERRUCOUS CARCINOMA:  
Verrucous carcinoma is a variant of well differentiated SCC endowed with 
enough clinical, pathologic, and behavioral peculiarities to justify it being regarded 
as a specific tumor entity.103-106 Within the oral cavity the most common sites are 
buccal mucosa and lower gingiva.107 Most patients are elderly males and there is a 
close connection with the use of tobacco especially chewing or snuff dipping. 
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Grossly it presents as a large fungating soft papillary growth that tends to become 
infected and slowly invades contiguous structures. It may grow through the soft 
tissues of the cheek, penetrate into the mandible or maxilla, and invade perineurial 
spaces. Regional lymphnode metastasis is exceedingly rare, and distant 
metastases have not been reported. Microscopically verrucous carcinoma shows 
hyperkeratosis, acanthosis, benign appearing papillomatosis, and most importantly 
swollen and voluminous rete pegs that extend into the deeper tissues.108 The most 
important differential feature with a case of well differentiated squamous cell 
carcinoma is a good cytological differentiation throughout the tumor. 
OTHER MICROSCOPIC SUBTYPES:  
Adenoid (Pseudo glandular) squamous cell carcinoma: This tumor 
exhibits a pseudo-glandular or alveolar appearance because of acantholysis. 
Adenosquamous carcinoma: In contrast to the above, this rare variant 
shows areas of squamous differentiation mixed with others having true 
glandular differentiation.109, 110 
Basaloid squamous cell carcinoma: This is an aggressive variant of 
squamous cell carcinoma that has a predilection for the upper aerodigestive 
tract. Microscopically areas with obvious squamous differentiation are 
admixed with solid tumor islands that exhibit peripheral palisading on a thick 
basement membrane which is one of the striking attributes of this tumor.111 
Spindle cell carcinoma: In this tumor the sarcoma like formation blends with 
areas of obvious squamous cell carcinoma or is associated with squamous 
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cell carcinomas elsewhere in the oral cavity or represents the recurrence of 
an original squamous cell carcinoma.112-115 
Papillary squamous cell carcinoma: The histological feature of this type 
includes the presence of a papillary display of fibrovascular cores lined by 
markedly dysplastic squamous epithelium. 
Lymphoepithelioma: This is a histological variant of SCC in which there is 
intermingling of undifferentiated carcinoma cells with prominent lymphoid stroma.   
LOCAL AND DISTANT METASTASIS:  
SCC of the upper aerodigestive tract (UADT-SCC) predominantly 
metastasizes to the lymphnodes of the neck, the site of the involved nodes 
being dependant on the localization of the primary tumor.116, 117 The adverse 
influence of metastatic neck node deposits on patient survival is firmly 
established, the prognosis being diminished roughly by half if lymphnode 
metastases are present at presentation or during follow-up.118, 119 Prognosis 
further worsens if the tumor spreads beyond the lymphnode into the soft 
tissues of the neck; this growth pattern is known as extracapsular spread. 
Neck node disease also correlates with increased risk for development of 
distant metastasis. Patients with disease in the neck had twice as many distant 
metastasis as those without (13.6% vs 6.9%), whereas the presence of 
extranodal spread meant a 3-fold increase in the incidence of distant metastasis, 
compared with patients without this feature. The occurrence of distant 
metastasis of UADT-SCC has been proved to predominantly occur in the lungs. 
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Thus, the prognostic significance of neck node disease justifies a very 
meticulous examination of neck dissection specimens, as a high incidence of 
micrometastasis (<3mm) has been found in patients without clinically manifest 
neck disease. Therefore, one should realize that, although pretreatment 
evaluation of nodal status in many institutions is based on palpation, 
depending on palpation for detection or exclusion of nodal involvement has 
proven unreliable; nevertheless, it remains part of the initial staging. 
WHO CLASSIFICATION OF TUMORS OF ORAL CAVITY AND OROPHARYNX 
Malignant epithelial tumours: 
Squamous cell carcinoma 
Verrucous carcinoma 
Basaloid squamous cell carcinoma 
Papillary squamous cell carcinoma 
Spindle cell carcinoma 
Acantholytic squamous cell carcinoma 
Adenosquamous carcinoma 
Carcinoma cuniculatum 
Lymphoepithelial carcinoma 
Epithelial precursor lesions 
Benign epithelial tumours 
Papillomas 
Squamous cell papilloma and verruca vulgaris 
Condyloma acuminatum 
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Focal epithelial hyperplasia 
Granular cell tumour 
Keratoacanthoma 
Salivary gland tumours 
Salivary gland carcinomas 
Acinic cell carcinoma 
Mucoepidermoid carcinoma 
Adenoid cystic carcinoma 
Polymorphous low-grade adenocarcinoma 
Basal cell adenocarcinoma 
Epithelial-myoepithelial carcinoma 
Clear cell carcinoma, not otherwise specified 
Cystadenocarcinoma 
Mucinous adenocarcinoma 
Oncocytic carcinoma 
Salivary duct ca rcinoma 
Myoepithelial carc inoma 
Carcinoma ex pleomorphic adenoma 
Salivary gland adenomas 
Pleomorphic adenoma 
Myoepithelioma 
Basal cell adenoma 
Canalicular adenoma 
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Duct papilloma 
Cystadenoma 
Soft tissue tumours 
Kaposi sarcoma 
Lymphangioma 
Ectomesenchymal chondromyxoid tumour 
Focal oral mucinosis 
Congenital granular cell epulis 
Haematolymphoid tumours 
Diffuse large B-celilymphoma (DlBCl) 
Mantle cell lymphoma 
Follicular lymphoma 
Extranodal marginal zone B-cell lymphoma of MALT type 
Burkitt lymphoma 
T-cell lymphoma (including anaplastic large cell lymphoma  
Extramedullary plasmacytoma 
Langerhans cell histiocytosis 
Extramedullary myeloid sarcoma 
Follicular dendritic cell sarcoma I tumour 
Mucosal malignant melanoma 
Secondary tumours 
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TNM CLASSIFICATION OF CARCINOMAS OF ORAL CAVITY AND OROPHARYNX: 
 
31 
 
PROGNOSTIC AND PREDICTIVE FACTORS: 
Tumor size and nodal status are the most significant prognostic 
factors. 120 Histological grade correlates poorly with patient outcome.121, 122 
The value of grading improves when only deeply invasive margins of the 
tumor are evaluated.123, 124 Tumors invading with pushing borders are less 
aggressive than tumors with a non-cohesive front showing diffuse spread with 
tiny strands or single cells.125-127 Major risk factors that adversely influence 
prognosis are 2 or more positive regional nodes, extracapsular extension of 
nodal disease, or positive margins of resection.128 Other important histological 
features associated with poor prognosis are tumor thickness and vascular 
invasion. Molecular markers with unequivocal prognostic and/or predictive 
significance have not been identified.129-131 
FUTURE DIRECTIONS AND CLINICAL APPLICATIONS: 
The oral cancer problem primarily involves the understanding, 
diagnosis, and treatment of squamous cell carcinoma of the oral cavity.132 
While recent advances have reduced the morbidity of oral cancer, the  
five-year survival rate for these patients has remained largely unchanged  
at ~ 50% for the last 30 years, because early stages of the disease are 
associated with minimal signs and symptoms, and advanced stages generally 
respond poorly to current cancer therapies.132  The ability to map the 
signature cell cycle defects in human oral cancer is of value not only for the 
biological understanding of the disease but more importantly toward the 
translational utilization of this information for early diagnosis and biology-
32 
 
based therapy. Many of the cell cycle regulators reviewed have been 
associated as biologic predictors of oral cancer behavior. In the future, our 
ability to profile, comprehensively, the gene expression differences among 
normal, pre-malignant, and tumor cells from the same patient will allow us 
better to index the consistently altered cell cycle defects in human oral 
cancer.133 
Development of new animal models will advance our understanding of 
the functional consequences of these cell cycle defects. Understanding the 
identity and function of oral cancer cell cycle defects will provide novel 
biological/genomic parameters for patient outcome monitoring and treatment 
therapy decisions and options. Two new head and neck cancer therapeutic 
approaches under investigation are cell-cycle-based. ONYX-015 is an E1B 
attenuated adenovirus that is believed to replicate selectively in p53 mutant 
cells, therefore sparing normal/wild-type p53 cells. However, other studies fail 
to correlate mutant p53 and viral replication.134 When administered 
intratumorally to patients with recurrent head and neck cancer, ONYX-015 
produced tumor necrosis in four of five patients with mutant p53.135 ONYX-
015 treatments, which were easily administered and well-tolerated, may serve 
as an adjunct to current chemotherapeutic approaches to head and neck 
cancer patients. Recently, a phase II trial on recurrent head and neck cancers 
was completed, demonstrating improved response to intratumoral ONYX-015 
injection with cisplatin and 5-fluorouracil vs. either viral treatment or 
chemotherapy alone.136 Flavopiridol is a novel cyclin-dependent kinase inhibitor 
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that has been demonstrated to have anti-neoplastic properties.137 Recently, 
flavopiridol has been shown to suppress head and neck carcinoma growth by 
inducing apoptosis.138 Exposure of malignant oral keratinocytes to flavopiridol 
diminished CDC2 and CDK2 activity, as well as reduced cyclin D1 expression. 
Certainly, understanding the mechanisms of cell cycle dysregulation of the oral 
keratinocyte during oral carcinogenesis will serve as an adjunct to present 
diagnostic and therapeutic options and provide the basis for novel strategies 
in the future.  
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MATERIALS AND METHODS 
 
STUDY CHARACTERISTICS: 
Twenty five patients with in situ and invasive oral SCC and its variant 
verrucous carcinoma who attended the out-patient department of Coimbatore 
Medical College Hospital between April 2008 and March 2009 were randomly 
included in our study. The immuno expression of the molecular markers 
(cyclin D1, p53, and CD44) were studied in their tissue sections and 
correlated with the degree of differentiation of the tumor and its association 
with cervical lymph node metastasis was analyzed. 
PATIENT CHARACTERISTICS: 
 Only those patients with newly diagnosed oral SCC were included in 
the study. Patients who presented with regional lymph node involvement were 
also included in the study. Patients with distant metastasis were excluded by 
using X-ray of the chest, ultrasound of the abdomen and CT scan of the brain. 
Those patients with oral SCC who had history of recurrence of the tumor, 
prior radiotherapy or surgery for the tumor were excluded from the study. 
Patients suffering from other primary malignancies and systemic illness were 
also excluded from the study.  
SAMPLES:  
In all the patients the primary tumor was confined to one of the 
following anatomical locations within the oral cavity including buccal mucosa, 
tongue, lip, alveolar margin, retromolar trigone, tonsil, floor of mouth and 
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palate. So the total of 25 patients yielded 25 samples that comprised of  
23 incisional biopsies obtained at the time of initial diagnosis and 2 wide 
excision specimens from patients curatively resected for cancer. Split up of 
the specimens showed their origin to be 6 each from buccal mucosa and 
tongue, 3 each from lip and alveolar margin, 2 each from retromolar trigone, 
tonsil, and palate and one from floor of mouth. 
 For histopathological and immunohistochemical studies the tumor 
samples were fixed in 10% buffered formalin and then embedded in paraffin. 
The diagnosis was confirmed by routine histopathological examination using 
hematoxylin and eosin stain. For immunohistochemical studies, 4 micrometer 
thick tissue sections were taken in specially coated slides using chrome-alum 
and gelatin. The tissue sections included not only tumor lesions but also the 
adjacent non-tumorous oral epithelium in few cases that served as internal 
controls for immunohistochemistry. 
In patients with enlarged cervical nodes, fine needle aspiration was 
done and the cytology smear was examined to confirm the presence of 
metastatic deposit. 
IMMUNOHISTOCHEMISTRY: 
PRINCIPLE: 
The demonstration of antigens in tissues and cells by immunostaining 
is a 2-step process involving first, the binding of an antibody to the antigen of 
interest and second, the detection and visualization of bound antibody by one 
of a variety of enzyme chromogenic system. In our study we have used  
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“The Super Sensitive Polymer-HRP Detection System” that is based on a 
non-biotin polymeric technology that makes use of 2 major components: 
Super Enhancer and a Poly-HRP reagent. As the system is not based on the 
Biotin-Avidin system the problems associated with endogenous biotin are 
completely eliminated. In this technique a large number of peroxidase 
enzyme molecules are bound to a secondary antibody via the dextran 
backbone. This was done to increase the sensitivity.  
SIMPLE PROTOCOL : 
1. Application of primary antibody  
2. Application of enzyme labeled polymer  
3. Application of the substrate chromogen  
EVALUATION OF IMMUNOHISTOCHEMICAL STAINING:  
The most representative tumor areas were selected for scoring the 
immunostaining pattern. The scoring was done using light microscopy.  
The following criteria were used to study the distribution and intensity of positive 
tumor cell staining. Nuclear coloration was considered as a positive reaction for 
p53 and Cyclin D1 and cell membrane staining was considered as a positive 
reaction for CD44.  
P53 AND CYCLIN D1 SCORING SYSTEM: 139 
Distribution: Absent tumor cell staining was scored as 0, <10% of 
positive tumor cells staining were scored as 1, 10% to 50% of cells staining 
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were scored as 2, 50% to 90% of cells staining were scored as 3, and >90% 
cells staining were scored as 4. 
Intensity: Absent staining in tumor cells was scored as 0, equivocal 
was scored as 1, clearly positive was scored as 2, and strong positive staining 
was scored as 3. 
The results for intensity and distribution were summed and a "score" 
was assigned from 0 to 7. Over expression for each of these antibodies was 
assigned when a score of ≥ 4 was obtained. 
CD44 SCORING SYSTEM: 
The degree of positive staining for CD44 antibody was evaluated by a 
well-established semiquantative scoring on a scale of 1 to 4 for intensity  
(I) such as none, mild, moderate and strong, and for distribution (D) such as 
none, focal, patchy and diffuse (7). Tissues with I x D less than or equal to 
four were considered weakly positive and those with I x D greater than four 
were designated strongly positive. 
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OBSERVATION AND RESULTS 
 
Table I: Demographics 
Parameter Value 
Age (Mean ± SD) 57.08 ± 11.17 (40-80) YEARS 
Sex (Male : Female) 13:12 (52/48)% 
Alcohol use 40% 
Tobacco use 92% 
Diabetes 20% 
Hypertension 24% 
Radiation exposure 0% 
Family history 0% 
Immune defects 0% 
Occupational exposure 0% 
 
Table I shows the demographic characteristics of our study population. 
The mean age of the patients was 57.08 ± 11.17 years and the youngest patient 
was 40 years and eldest was 80 years old. Almost half of the patients (48%) 
were females. Almost all (92%) patients were tobacco users in the form of 
smoking, chewing or snuffing. Among them 9 (39%) were smokers, 12 (52%) 
were chewers, and 2 (8%) were snuffers. Among males (13) 9 (69%) were 
smokers, one was a chewer, and 2 were snuffers. Among females almost all of 
them (92%) were chewers. Forty percent of the patients were alcoholics. Five 
patients (20%) were diabetics and six (24%) were hypertensives. No patients 
had other risk factors for oral carcinoma like exposure to radiation, family history 
of cancer, immune deficiency or occupational exposure to carcinogens. 
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Table II: Clinical and Histopathological Characteristics  
EXPOSURE 
S. NO AGE SEX SPEα SITE 
TOBACCO   ALCOHOL
HISTOLOGYβ GRADEγ ADJ EPIε
NODAL 
STATUSζ
1          46 M WB BUCCAL MUCOSA SMOKER PRESENT VC WDv + NAP
2 60 M WB ALVEOLAR MARGIN SMOKER PRESENT In SCC MD - - 
3 50 F WB RETROMOLAR TRIGONE CHEWER ABSENT In SCC MD + + 
4 50 M WB FLOOR OF MOUTH SMOKER ABSENT In SCC MD + + 
5 65 M WB TONSIL SMOKER PRESENT  INSITU SCC NAP + NAP 
6          70 M WB TONGUE SMOKER PRESENT In SCC MD - -
7          68 M WB PALATE SNUFFER PRESENT In SCC MD + +
8 80 F WB BUCCAL MUCOSA CHEWER ABSENT INSITU SCC NAP + NAP 
9          40 F WB TONGUE CHEWER ABSENT In SCC MD + +
10          47 F WEB TONGUE CHEWER ABSENT In SCC WD + +
11 70 M WB BUCCAL MUCOSA SNUFFER ABSENT In SCC WD + + 
12 NA M WB BUCCAL MUCOSA SMOKER PRESENT In SCC MD + - 
13           52 F WB PALATE CHEWER ABSENT In SCC MD - -
14 64 F WB ALVEOLAR MARGIN CHEWER ABSENT In SCC WD - - 
15           67 M WB TONGUE CHEWER PRESENT In SCC WD + -
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Table II.  Contd.. 
EXPOSURE 
S. NO AGE SEX SPEα SITE 
TOBACCO   ALCOHOL
HISTOLOGYβ GRADEγ ADJ EPIε
NODAL 
STATUSζ
16           40 F WB LIP NONE ABSENT VC WDv + NAP
17 43 M WB BUCCAL MUCOSA NONE PRESENT In SCC MD + - 
18           53 M WB TONGUE SMOKER PRESENT In SCC WD + +
19           60 F WB LIP CHEWER ABSENT In SCC MD + -
20           70 F WB TONGUE CHEWER ABSENT In SCC WD - -
21          70 F WEB TONGUE CHEWER ABSENT VC WDv + NAP
22           50 F WB LIP CHEWER ABSENT VC WDv + NAP
23           58 M WB TONSIL SMOKER ABSENT In SCC PD + -
24 45 M WB RETROMOLAR TRIGONE SMOKER PRESENT In SCC PD - - 
25 46 M WB ALVEOLAR MARGIN CHEWER ABSENT In SCC WD - - 
 
α:WB- Wedge Biopsy, WEB- Wide Excision Biopsy. β: VC- Verrucous Carcinoma, In SCC-Invasive Squamous  
Cell Carcinoma, INSITU SCC-Insitu Squamous Cell Carcinoma. γ:WD- Well Differentiated,  
WDv- Variant of Well Differentiated, MD- Moderately Differentiated, PD- Poorly Differentiated. ε: - - Absent, +- Present.  
ζ: NAP- Not Applicable,- -Absent, +- Present. 
Table II shows the clinical and histopathological characteristics of the individual patients.  
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Table III: Nature of specimen 
Sl.No Nature of the Specimen No of Patients (Percentage) 
1 Incisional biopsy 23 (92%) 
2 Wide excision biopsy 2 (8%) 
 
Table III shows the type of specimens obtained for our study. The total 
of 25 patients yielded 25 samples among which only 2 were wide excision 
biopsies that were obtained during the curative resection of the tumor. All the 
rest were specimens obtained at the time of incisional biopsies done for the 
initial diagnosis of the lesion. 
 
Nature of the Specimen
Wedge Biopsy
92%
Wide Excision 
Biopsy
8%
 
Figure 6: Pie diagram of the nature of the specimen 
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Table IV: Distribution of the tumor within the oral cavity 
Sl.No SITE OF THE TUMOR Number of Patients Percentage
1 TONGUE 6 24 
2 BUCCAL MUCOSA 6 24 
3 LIP 3 12 
4 ALVEOLAR MARGIN 3 12 
5 TONSIL 2 8 
6 RETROMOLAR TRIGONE 2 8 
7 PALATE 2 8 
8 FLOOR OF THE MOUTH 1 4 
 
Table IV shows the distribution of the tumor site within the oral cavity. Split up 
of the specimens showed their origin to be 6 each from buccal mucosa and tongue, 3 
each from lip and alveolar margin, 2 each from retromolar trigone, tonsil, and palate 
and one from floor of mouth. 
Distribution of the Tumor
12%
12%
24%
24%
8%
8%
8% 4%
TONGUE BUCCAL MUCOSA
LIP ALVEOLAR MARGIN
TONSIL RETROMOLAR TRIGONE
PALATE FLOOR OF THE MOUTH
 
Figure 7: Pie chart depicting the distribution of the tumor 
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Table V: Histopathological grading and typing 
Histological Type Grade Number of Cases 
Carcinoma Insitu - 2 
Well Differentiated 7 
Moderately Differentiated 10 Invasive Carcinoma 
Poorly Differentiated 2 
Verrucous 
Carcinoma 
Variant of well differentiated 
carcinoma 
4 
 
Table V shows the distribution of the tumor by their different grades and 
types. Three forths (19) of the tumors were invasive SCC. Insitu and verrucous 
carcinoma contributed to 8% and 16% of the tumors respectively. Among the 
invasive SCC, half the tumors were moderately differentiated and were closely 
followed by the well differentiated SCC amounting to 37%. Poorly differentiated 
SCC contributed to only 10% of the invasive SCC in our study. 
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Table VI: Metastasis to regional lymph nodes in Invasive OSCC (n=19) 
Nodal Metastasis Number of Cases Percentage 
Positive 7 37 
Negative 12 63 
 
Table VI shows the details of the metastatic regional lymph node 
involvement in patients with invasive SCC. Seven (37%) of the 19 patients 
had regional cervical lymph node enlargement. According to the protocol 
these patients underwent fine needle aspiration (FNA) and the presence of 
metastatic deposits from the primary tumor was confirmed. 
 
Regional Lymphnode involvement 
37%
63%
Positive Negative
 
Figure 8: Pie diagram showing the regional lymphnode involvement 
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 PATTERNS OF IMMUNOSTAINING OF THE MOLECULAR MARKERS:  
Immunostaining for p53 and Cyclin D1 primarily demonstrated a 
nuclear staining pattern. Staining for CD44 primarily demonstrated a 
membrane pattern of staining with a rare component of cytoplasmic staining 
and no nuclear staining. Immuno study in our work was based only on 
membrane staining. Lymphocytes and inflammatory cells stained intensely for 
CD44 but were excluded from analysis. Figure 9 to 11 shows the 
immunostaining patterns of the molecular markers studied. 
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Table VII: Status of the adjacent epithelium 
Status of the adjacent epithelium No of cases 
Absent  7 
Normal/Hyperplastic 15 Present 
Dysplastic 3 
 
Table VII shows the details of the adjacent non-tumoral epithelium. 
Adjacent epithelium was present only in 18 (72%) of the 25 cases studied. 
Among them 3 (17%) showed mild to moderate dysplasia and the remaining 
15 (83%) of the specimens showed normal or hyperplastic adjacent 
epithelium.  
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Table VIII: Expression of Molecular Markers in the Adjacent Epithelium  
P53 CYCLIN D1 CD44 
S.NO HPE NO ADJ EPI 
EXP INT EXP INT EXP INT 
1 1023/08 Present 1 4 3 3 3 3 
2 108/09 Absent NAP NAP NAP NAP NAP NAP 
3 119/09 Present 3 3 2 2 3 3 
4 120/09 Dysplastic 4 4 4 4 4 4 
5 1369/08 Absent NAP NAP NAP NAP NAP NAP 
6 1601/09 Present 1 3 2 4 3 4 
7 1604/09 Absent NAP NAP NAP NAP NAP NAP 
8 1608/08 Present 3 4 3 4 3 3 
9 1943/08 Absent NAP NAP NAP NAP NAP NAP 
10 2328/08 Present 3 3 3 4 3 1 
11 2348/08 Dysplastic 4 4 4 4 4 4 
12 2379/08 Dysplastic 4 4 4 4 4 4 
13 2525/08 Present 3 3 2 4 3 3 
14 2581/08 Present 3 3 2 4 3 4 
15 2717/08 Present 1 2 2 3 3 3 
16 2718/08 Absent NAP NAP NAP NAP NAP NAP 
17 2765/08 Absent NAP NAP NAP NAP NAP NAP 
18 2798/08 Present 1 2 2 3 3 3 
19 2817/08 Present 1 3 2 3 1 4 
20 2827/08 Present 1 4 2 4 3 2 
21 644/08 Present 3 4 2 4 3 3 
22 66/09 Present 1 4 2 4 3 3 
23 763/08 Absent NAP NAP NAP NAP NAP NAP 
24 857/08 Present 1 4 2 4 3 4 
25 926/08 Present 1 4 3 4 3 1 
 
EXP: Expression (Scoring: 1-Basal layer; 2-Suprabasal layer; 3- Both basal 
and suprabasal layers; 4-Entire dysplastic area). INT: Intensity (Scoring: 1-Weak; 
2-Mild; 3-Moderate; 4-Strong). NAP: Not Applicable. 
Table VIII shows the expression of molecular markers in the adjacent 
epithelium.  
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In the sections that had normal or hyperplastic adjacent epithelium the p53 
staining was expressed predominantly in the basal layer in 9 cases and both basal 
and suprabasal layers in 6 cases and the intensity was variable. The cyclin D1 
staining was predominantly suprabasal in 11 cases and both basal and 
suprabasal in the remaining 4 cases. The CD44 staining was present in both the 
basal and suprabasal layer in all of them except one that had the staining 
restricted to the basal layer alone. The intensity of the staining for all the three 
molecular markers was predominantly moderate or strong. 
In the three sections that showed mild to moderately dysplastic adjacent 
epithelium the intensity of the staining for all the 3 molecular markers was strong. 
The expression was found to be present involving the entire dysplastic area.  
Table IX: Expression of molecular markers in insitu oral cancer 
P53 CYCLIN D1 CD44 
SITE 
EXP EXT INT TS EXP EXT INT TS EXP EXT INT TS 
TONSIL + 4 3 7 + 4 3 7 + 4 4 16 
BUCCAL MUCOSA + 4 3 7 + 1 3 4 + 2 3 6 
EXP- Expression; EXT-Extent; INT-Intensity; TS- Total Score 
Table IX shows the expression and scoring of immunostaining of the 
various molecular markers in cases of in situ oral SCC. All the 3 molecular 
markers were over expressed in both the cases. 
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Table X: Distribution of molecular markers in patients with Oral SCC 
P53 Cyclin D1 CD 44 
S.NO HPE No 
Exp Ext Int TS Exp Ext Int TS Exp Ext Int TS
1 108/09 + 3 3 6 + 2 3 5 - 1 1 1 
2 119/09 + 3 2 5 + 3 2 5 - 1 1 1 
3 120/09 + 3 3 6 + 1 3 4 + 2 2 4 
4 644/08 + 3 3 6 + 3 2 5 + 4 3 12 
5 763/08 + 3 3 6 + 1 1 2 + 2 2 4 
6 857/08 + 3 3 6 + 2 2 4 + 3 3 9 
7 926/08 + 2 3 5 + 2 3 5 + 3 3 9 
8 1023/08 + 2 3 5 + 2 3 5 + 3 3 9 
9 1369/08 + 2 2 4 + 1 1 2 - 1 1 1 
10 1601/09 + 4 3 7 + 3 3 6 + 4 4 16 
11 1604/09 + 4 3 7 + 1 2 3 + 2 2 4 
12 1608/08 + 4 3 7 + 4 3 7 + 4 4 16 
13 1943/08 + 3 2 5 + 1 2 3 + 2 3 6 
14 66/09 + 4 3 7 + 3 3 6 + 3 4 12 
15 2328/08 + 4 3 7 + 4 3 7 + 3 3 9 
16 2348/08 + 4 3 7 + 1 3 4 + 2 3 6 
17 2379/08 + 3 3 6 + 3 3 6 + 4 4 16 
18 2525/08 + 3 3 6 + 2 3 5 - 1 1 1 
19 2581/08 + 3 3 6 + 3 3 6 + 2 2 4 
20 2717/08 + 2 1 3 + 2 2 4 + 3 3 9 
21 2718/08 + 3 3 6 + 3 3 6 + 3 3 9 
22 2765/08 + 3 2 5 + 2 2 4 + 3 4 12 
23 2798/08 + 2 1 3 + 2 2 4 + 3 4 12 
24 2817/08 + 2 3 5 + 2 3 5 + 3 4 12 
25 2827/08 + 3 1 4 + 2 2 4 + 3 3 9 
Exp- Expression; Ext- Extent; Int-Intensity; TS- Total Score.  
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Table X shows the distribution (extent and intensity) of the molecular 
markers in our study population. The intensity and extent of staining was 
quantified systematically as mentioned before. A total score was derived from 
the intensity and extent of staining. For p53 and cyclin D1 the total score was 
calculated as the sum of the individual scores obtained for the extent and 
intensity of staining. Whereas for CD44 it is the product of the individual scores 
obtained for the extent and intensity of staining. All the cases exhibited positive 
staining for p53 and Cyclin D1 as compared to CD44 that was negative for 
immunostaining in 4 cases. Although majority of the cases were positive for 
immunostaining the extent and intensity of the staining varied among the cases.  
Table XI: Distribution of immunohistochemical scoring in Oral SCC 
Molecular 
Marker P53 Cyclin D1 CD44 
Total Score 0 1-3 4-5 6-7 0 1-3 4-5 6-7 1-4 5-8 9-12 13-16 
Total 
Cases 
In situ 0 0 0 2 0 0 1 1 0 1 0 1 2 
WD 0 1 2 4 0 2 4 1 4 0 3 0 7 
MD 0 1 3 6 0 1 5 4 3 1 5 1 10 
Invasive 
oral SCC 
PD 0 0 0 2 0 1 0 1 1 0 0 1 2 
Verrucous 
carcinoma 
0 0 3 1 0 0 4 0 0 0 4 0 4 
Total 0 2 8 15 0 4 14 7 8 2 12 3 25 
 
WD: Well Differentiated; MD: Moderately Differentiated; PD-Poorly Differentiated 
Table XI shows the distribution of the total score for the molecular 
markers p53, cyclin D1 and CD44. Total scores obtained from the 
immunohistochemical study for the 3 markers were analyzed to find the 
frequency of distribution of the scores among the different grades of oral SCC 
and in verrucous carcinoma.  
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p53 immunostaining revealed that the total score was predominantly in the 
higher side in insitu and invasive SCC. But, three fourths of verrucous carcinoma 
had their total scores in the mid-range (4 to 5). Cyclin D1 immunostaining revealed 
that the total score was predominantly in the mid-range (total score-4 to 5) 
including all the cases of verrucous carcinoma. CD44 immunostaining revealed 
that the total score was predominantly in the range of 9 to 12.  
Table XII: Relationship between over expression of molecular markers 
and Histological Grade in invasive oral cancer 
P53 over 
expression  
(Total Score ≥ 4) 
CyclinD1 over 
expression 
(Total Score ≥ 4) 
CD44 Strong 
positivity 
(Total Score > 4) 
Histological 
grade N 
Absent Present Absent Present Absent Present 
Well 
differentiated 
7 1 6 2 5 4 3 
Moderately 
differentiated 
10 1 9 1 9 3 7 
Poorly 
differentiated 
2 0 2 1 1 1 1 
Total cases 19 2 17 4 15 8 11 
 
Table XII shows the relationship between over expression of molecular 
markers and histological grade in invasive oral cancer. For the complexity of 
analysis of the different ranges in the total scores of the staining of the 3 molecular 
markers a simplified method was followed as mentioned before in the scoring 
system. A cut off value for total score of 3 for p53 and Cyclin D1 and 4 for CD44, 
above which the molecular markers were defined as overexpressed. 89%, 79% 
and 58% of the cases of invasive SCC were found to overexpress  p53, Cyclin D1 
and CD44 respectively.  
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Table XIII: Overexpression of molecular markers in Insitu and Invasive 
SCC vs Verrucous Carcinoma 
Overexpression of Molecular 
Markers 
Insitu and Invasive 
SCC 
Verrucous 
Carcinoma 
P53  19/21 4/4 
Cyclin D1  17/21 4/4 
CD44  13/21 4/4 
 
 Table XIII shows a comparison of molecular markers over expression 
in SCC and its variant verrucous carcinoma. 
We wanted to analyze if there is any statistically significant relationship 
between the tumor grade and the degree of expression of the molecular 
markers. To simplify the analsysis we studied the correlation of the grade of the 
tumor with the presence or absence of over expression of the molecular 
markers. 
Table XIV: Correlation of Histological Grade with degree of expression of 
Molecular Markers in Invasive Oral SCC 
 Total P53 
Score 
Total Cyclin D1 
Score 
Total CD44 
Score 
Correlation 0.379 0.232 0.192 
P value 0.110 0.339 0.430 G
ra
de
 
Number of 
Cases 
19 19 19 
 
Table XIV shows the statistical Pearsons correlation of histological 
grade with the presence or absence of over expression of molecular markers. 
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The analysis revealed insignificant statistical correlation between the 
histological grades and over expression of molecular markers. Within the 
molecular markers, over expression of p53 showed slightly higher correlation 
(p=0.110) than that of cyclin D1 and CD44 although without any statistical 
significance. Comparing Cyclin D1 and CD44, Cyclin D1 (0.339) showed 
better correlation than CD44 (0.430) again without any statistical significance. 
Table XV: Expression of molecular markers in patients with cervical 
node metastasis 
P53 Cyclin D1 CD 44 
HPE No 
Ext Int TS Ext Int TS Ext Int TS 
644/08 3 3 6 3 2 5 4 3 12 
2328/08 4 3 7 4 3 7 3 3 9 
2379/08 3 3 6 3 3 6 4 4 16 
2525/08 3 3 6 2 3 5 1 1 1 
119/09 3 2 5 3 2 5 1 1 1 
120/09 3 3 6 1 3 4 2 2 4 
2581/08 3 3 6 3 3 6 2 2 4 
 
EXP- Expression; EXT-Extent; INT-Intensity; TS- Total Score 
Table XV gives an idea about the expression of molecular markers in 
case of invasive SCC with regional cervical node metastasis. Overexpression 
of p53 and Cyclin D1 was observed in all the 7 cases with nodal metastasis 
whereas strong positivity for CD44 was observed only in 3 cases.   
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Table XVI: Correlation of Biomarker Expression and cervical node 
metastasis in Invasive Oral SCC 
Nodal Metastasis 
Biomarker Total score 
No of 
cases Present Absent 
Chi Sq 
value 
P 
value 
<4 2 0 2 P53 
≥4 17 7 10 
0.135 0.714 
<4 4 0 4 Cyclin D1 
≥4 15 7 8 
1.290 0.256 
≤4 8 4 4 CD44 
>4 11 3 8 
0.283 0.594 
 
Table XVI shows the statistical analysis done to look for any significant 
relationship between degree of expression of molecular markers and the 
status of the nodal involvement. Chi-square test was used to evaluate the 
statistical significance. None of the 3 molecular markers expressed showed 
any statistically significant relationship with the nodal metastasis.  
Table XVII: Relationship between p53, cyclin D1 and CD44 expression in 
oral cancer 
Molecular markers P53 Cyclin D1 
CyclinD1 
n 
<4 ≥4 p Value <4 ≥4 P Value 
<4 4 0 4    
≥4 21 2 19 
0.868 
   
CD44  
≤4 8 0 8 3 5 
>4 17 2 15 
0.872 
1 16 
0.154 
Table XVII shows the statistical analysis done to study the relationship 
between expression of all the 3 molecular markers in oral SCC and its variant 
verrucous carcinoma. Results were found to be statistically insignicant. 
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Table XVIII: Expression of molecular markers in verrucous oral cancer 
P53 CYCLIN D1 CD44 
HPE NO SITE 
EXP EXT INT TS EXP EXT INT TS EXP EXT INT TS
1023/08 4 P 2 3 5 P 2 3 5 P 3 3 9 
2817/08 1 P 2 3 5 P 2 3 5 P 3 4 12 
857/08 4 P 3 3 6 P 2 2 4 P 3 3 9 
926/08 1 P 2 3 5 P 2 3 5 P 3 3 9 
SITE 4: Buccal Mucosa, 1: Lip  
Table XVIII shows the expression and scoring of immunostaining of the 
various molecular markers in cases of verrucous carcinoma. All the 3 molecular 
markers were over expressed in all the 4 cases. The staining for the molecular 
markers was predominantly observable in the pushing margin of the tumor in 
most of the cases reflecting the maximum proliferative activity of this tumor in 
these areas. The staining tends to diminish in the superficial areas that could 
represent the more differentiated part of the tumor where the cells have stopped 
proliferating. 
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DISCUSSION 
 
The majority of oral cancers are SCC, and numerous studies have 
been done on them with a prime objective of understanding the biology, 
diagnosis, prognosis, and management of this entity.140 Verrucous carcinoma 
(VC) is a low-grade variant of squamous carcinoma that shows distinct clinical 
and histological features and whose molecular alterations have not been 
extensively studied. The multistage process of carcinogenesis involves the 
progressive acquisition of mutations and epigenetic abnormalities in the 
expression of multiple genes that have highly diverse functions. An important 
group among these genes is involved in cell cycle control.141 So, we have 
studied the role of cell cycle regulators p53, cyclin D1 and the cell adhesion 
molecule, CD44 in tumor differentiation and regional node metastasis of oral 
SCC. 
AGE OF OCCURRENCE: 
The mean age of the patients included in our study was 57.08 years 
(Range 40-80 years). This is more or less similar to the observation made by 
Xu et al in which the mean age of the study group was 60 years (Range  
34-86).142 The mean age of presentation in another study done by Lam et al 
on oral SCC was 64 years (Range 37-85 years).143 
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TOBACCO AND ALCOHOL USAGE: 
In the study done by Xu et al on human oral carcinomas they found 
that all patients had a history of considerable current or previous use of 
tobacco use and 72% of the patients had history of alcohol abuse. 142  
In a study done by Maahs et al on 45 patients with oral SCC, 80% and 
56% of them had history of tobacco and alcohol use respectively.144 
Similarly, in our study some form of tobacco use was found in 92% of 
patients and alcohol use was found in 40% of patients. A slightly lesser 
percentage of alcohol use could be related to the higher number of female 
patients (M: F= 1.08:1) included in our study who are less likely to consume 
alcohol compared to the western population. 
SITE DISTRIBUTION: 
In a study done by Ozer et al on oral SCC the frequent tumor sites 
were tongue (40%), lips (25%) and gingiva (25%). In another study done by 
Lam et al on oral SCC the commonest sites of tumor were floor of the mouth 
and buccal mucosa.143  
The commonest tumor sites in our study group were tongue and 
buccal mucosa each contributing to about a quarter of patients and the least 
common site was floor of the mouth (4%). Rest of the sites showed almost 
equal distribution (around 10%).  
Vicente et al studied the significance of p53 expression in oral SCC 
without neck node metastases in 91 patients with oral SCC. In their study 
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well, moderately and poorly differentiated SCC contributed to 62%, 25% and 
4% of the cases respectively.145 
In a study done by Sano et al on 37 patients with oral SCC, well and 
moderately differentiated carcinoma and verrucous carcinoma contributed to 
73%, 21% and 6% of cases respectively.146 
In our study 75% of the tumors were invasive SCC and among the 
remaining quarter of the specimens verrucous carcinoma and in situ 
carcinoma contributed to 16 and 8%. Among the invasive SCC well, moderate 
and poorly differentiated formed 37%, 53% and 10% respectively.  
NECK NODE METASTASIS: 
Maahs et al in their study on 45 patients with SCC of mouth reported 
metastatic neck node involvement in 51% of their cases. 144 
In another study done by Vicente et al on 91 cases of oral SCC nodal 
involvement was found in 37% of cases.145 
Similarly, in our study, metastatic regional lymph node involvement 
was present in 37% of patients with invasive oral SCC.  
EXPRESSION OF MOLECULAR MARKERS IN THE ADJACENT NON-
TUMORAL EPITHELIUM AND CARCINOMA IN SITU: 
p53: 
Gonzalez-Moles et al 147 found that all normal epithelia adjacent to the 
tumor were p53-negative. p53 expression was detected in 25% of cases of 
adjacent hyperplastic epithelia and in 43% of cases with dysplasia adjacent to 
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the tumor. They concluded that the number of cases that expressed p53 
increased progressively with the severity of the epithelial disorder until the 
maximum percentage of positivity in tumor tissue was reached.  
Kerdpon et al in their study about the expression of p53 in oral 
mucosal hyperplasia, dysplasia and SCC observed a difference in staining 
pattern between the two groups, as p53-positive cells in lesions with benign 
hyperplasia generally were located in the basal and suprabasal layers, 
whereas dysplasias showed a varied staining, from confinement of  
p53-positive cells to the basal and parabasal layers in mild dysplasia to 
widespread staining in severe dysplasias.148 
In our study, the normal or hyperplastic epithelium adjacent to the 
tumor showed p53 expression predominantly in the basal layer in 60% of 
cases and in both the basal and suprabasal layers in rest of the cases. The 
intensity of staining was variable. In sections showing dysplastic changes in 
the adjacent epithelium there was a strong nuclear expression within the 
entire dysplastic area. Both the cases of carcinoma in situ studied showed full 
thickness strong nuclear expression for p53. 
Cyclin D1: 
Kuo et al found that positive cyclin D1 stain could be found in the 
normal appearing epithelium immediately adjacent to the SCCs in 54 of 73 
(74%) cyclin D1-positive cases and concluded that over expression of cyclin 
D1 may be an early event in oral carcinogenesis.149  
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Kotelnikov et al found that cyclin D1 positive cells are located mainly in 
suprabasal layers of oral epithelium in both truly normal and tumor-associated 
mucosa and also that the frequency of cyclin D1 positive cells in the basal 
layer is very low. 150 This was comparable to the finding in our study.  
This might be explained by the fact that only cells in suprabasal layers are 
proliferatively active in human oral epithelium from SCC patients. 
In our study, cyclin D1 expression in the adjacent normal or 
hyperplastic epithelium was predominantly present in the suprabasal layer in 
65% of the cases and was present in both the basal and suprabasal layers in 
rest of the cases. There was increased expression of cyclin D1 in all the 3 
cases with mild to moderate dysplasia in the adjacent epithelium. The increased 
expression of cyclin D1 was confined to the areas showing dysplasia. Of the2 
cases of carcinoma in situ, one showed full thickness strong nuclear 
expression for cyclin D1 whereas in the other case the strong nuclear 
expression was restricted to the suprabasal layer. The difference in 
expression of cyclin D1 in these 2 cases could not be explained. 
CD44: 
Roye et al studied the CD44 in dysplastic epithelium and SCC of 
esophagus and found that in normal (uninvolved) epithelium, immunostaining 
was strongest in the basal-cell layer and bottom third and weak or absent in 
the superficial layers. There was a significant increase in the intensity of 
immunostaining throughout all levels of the dysplastic epithelium, and the 
extent of this increase correlated directly with the severity of the dysplasia.151 
61 
 
Bankfalvi et al, in their study on gains and losses of adhesion 
molecules, found that there is constitutive expression of CD44 in the basal 
layer and lower part of the stratum spinosum in non-neoplastic oral 
epithelium. And they also found that there was increased expression of 
adhesion molecules with increase in dysplasia.152  
In our study, the CD44 staining pattern was predominantly confined 
both to the basal and suprabasal layers in the adjacent non-tumoral 
epithelium that was normal or hyperplastic. The dysplastic adjacent 
epithelium showed increased expression of CD44. Among the 2 cases of 
carcinoma in situ studied, one of them showed full thickness strong 
membranous expression for CD44 whereas in the other the staining was 
restricted to the basal layers. 
EXPRESSION OF MOLECULAR MARKERS IN ORAL SCC: 
Results from the study by Xu et al suggest that p53 mutations and 
cyclin D1 overexpression are common genetic events in oral cancer with 65% 
and 39% positivity for p53 and cyclin D1 respectively.142  
p53 and cyclin D1 expression was found in 46% and 39% respectively 
of the 140 patients with oral SCC studied by Shiraki et al.153 
In our study, p53, cyclin D1 and CD44 expression was present in 89%, 
79% and 58% respectively of the 19 cases with invasive SCC.  
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CORRELATION OF MOLECULAR MARKER EXPRESSION WITH 
HISTOLOGICAL GRADING AND NODAL METASTASIS 
p53: 
Nishioka et al 154 on a study in patients with oral SCC found a 
relationship between p53 expression and tumor grade, but not with the tumor 
stage. Vicente et al, in a study done on oral SCC, found a correlation of p53 
protein immunoexpression with histologic grade, but not with other clinical 
variables.145  
In contrast to the above finding, Yan et al in a study on carcinoma of 
buccal mucosa and tongue reported no correlation between p53 expression 
and tumor grade, disease stage, node status, or early local recurrence.155 
Similarly Lam et al in their study found no significant correlation between p53 
expression and grade of oral SCC.143  
Unal et al, in their study on p53 expression and histopathological 
parameters in SCC of tongue, found that p53 positivity statistically correlated 
with nodal metastasis.156 
Shiraki et al, in their study on oral cancer, found no statistical 
significance between p53 positivity and nodal metastasis.153 
In our study although over expression of p53 showed slightly higher 
correlation with the tumor grade than that of the cyclin D1 and CD44, it did not 
reach statistical significance. Similarly, there was no statisitically significant 
association between p53 over expression and nodal metastasis. 
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Cyclin D1: 
Angadi et al in their study regarding the cyclin D1 expression in various 
grades of oral SCCs reported a proportional increase in the percentage of 
positivity with increase in the cytological grade.157 This was in accordance 
with 2 other studies of oral SCC by Lam et al 143 and Miyamoto et al.158  
In a study by Wu et al.,159 cyclin D1 positivity was seen in 100% of 
well-differentiated SCC, 67% of moderately differentiated SCC, and 50% of 
poorly differentiated SCC, taking into consideration the number of positive 
cells. This study suggested a positive correlation of cyclin D1 expression with 
degree of differentiation, which is in contrast with our study where the cyclin 
D1 expression was correlating with the lack of differentiation of the tumor and 
increased with poor histological grade, that is, from well-differentiated SCCs 
to poorly differentiated SCCs.  
A similar study by Castle et al160 found no correlation with the degree 
of differentiation, as none of the poorly differentiated SCCs exhibited intense 
staining.  
In the literature, the association between cyclin D1 expression and the 
presence of neck node metastasis is ambiguous. Maahs et al studied 
expression of cyclin D1 by using immunohistochemical methods in 45 
patients with epidermoid carcinoma of the mouth and concluded that there is 
no association between expression cyclin D1 and neck node metastasis.144 
The results of the present investigation agree with those presented by  
Han et al,161 Michalides et al162, 163 and Bellacosa et al.164  
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However, there are papers from Frachiolla, 165 Itami,166 Masuda,167 
Tapia et al, Capaccio et al,168 and Mineta et al169 showing that expression of 
D1 cyclin is indeed associated with the presence of neck node metastasis. 
Results are contradictory and the reasons are not clear.  
Rodolico et al in their study 122 cases of lower lip SCC observed a 
67% cyclin D1 protein positivity; moreover multivariate analysis identified a 
significant independent predictive value for lymph node metastases 
occurrence.170  
Bova et al in their study on 148 tongue cancer patients showed that 
overexpression of cyclin D1 occurred in 68% of tumors and was associated 
with increased lymph node stage and  increased tumor grade.171  
In our study, there was no statistically significant relationship between 
cyclin D1 over expression with nodal metastasis or histological grade despite 
cyclin D1 over expression in 79% of cases of invasive oral SCC.  
CD44: 
Bankfalvi et al found that loss of CD44 and other adhesion molecules 
may be necessary to develop a definitively malignant phenotype with the 
ability to invade adjacent tissues. They concluded that some of the qualitative 
changes of adhesion molecule phenotype significantly signal poor outcome 
and/or forecast metastasis. 152  This fact was substantiated by the study on 36 
patients with SCC of tongue by Gonzalez-Moles et al that suggested a critical 
role for these invasion-related molecular processes in the prognosis of tongue  
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cancer patients. They stated that loss of CD44 and other adhesion molecules 
may be necessary to develop a definitively malignant phenotype with the 
ability to invade adjacent tissues.172 
Kunishi et al in their study concluded highly differentiated carcinomas 
displayed more intense CD44v6 reactivity than less differentiated ones 
without statistical significance. Their study also showed that oral SCC with 
low expression of CD44v6 more often had regional metastatic potential and 
may be related to lymph node metastasis. They all concluded that low 
expression of CD44v6 in oral SCC tissues may be an indicator of high 
metastatic potential and may also be related to lymph node metastasis.173 
Roye et al studied the CD44 expression in dysplastic epithelium and 
squamous cell carcinoma of the esophagus and observed that there was a 
decreased expression of CD44 in poorly differentiated esophageal SCC that 
may indicate an association of loss of CD44 expression with tumor 
progression.151 
Ozer et al in their study of 20 cases of oral SCC demonstrated that 
CD44 expression by tumor cells in oral cavity carcinomas statistically 
correlated with nodal metastasis. (ÖZER E., KUYUCUO–LU F. Correlation of 
CD44 expression with prognostic factors in oral squamous carcinoma. 
Eastern Journal of Medicine 4 (2): 61-64, 1999.) 
In the present study we did not find any statistically significant 
correlation of CD44 positivity with either histological grade or nodal 
metastasis. 
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VERRUCOUS CARCINOMA: 
Verrucous carcinoma of the oral cavity should be considered as a 
clinicopathologic entity, distinct from the more common SCC because of its 
unique biologic behavior. This tumor shows much slower growth with a limited 
propensity to metastasize and hence offers a better prognosis than SCC. 
Significant clinical and biologic differences are found between invasive SCC 
and verrucous carcinoma, which we attempted to evaluate using p53, cyclin 
D1 and CD44.  
In a study done by Angadi et al on Cyclin D1 expression in oral SCC 
and verrucous carcinoma, they found that 63% of the verrucous carcinoma 
was positive for cyclin D1. They also observed that the predominant intensity 
observed was mild.157 
In another study done by Gimenez-Conti et al in oral verrucous 
carcinoma 50% of them were positive for p53 staining and 61% of them 
expressed cyclin D1.174  
Ogawa et al recorded a difference in CD44v9 expression between 
verrucous carcinoma and well differentiated oral SCC of the tongue which 
was more frequently found in verrucous carcinoma. They concluded that this 
difference may be responsible for the variation in their metastatic capacity 
between these tumor types.175 
In our study, the 4 cases of verrucous carcinoma showed over 
expression of all the 3 molecular markers and the predominant intensity was 
moderate.  
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CONCLUSION 
 
1. The mean age of incidence of oral SCC in our study was 57 years with 
almost equal sex distribution. 
2. Ninety-two percent of the patients were tobacco users and 40% used 
alcohol. 
3. The most frequent sites of tumor within the oral cavity were tongue and 
buccal mucosa. 
4. Most (75%) of the cases were invasive SCC. Verrucous and insitu 
carcinomas contributed to 8% and 16% of cases respectively. 
5. Metastasis to the regional lymph node was found in 37% of cases of 
invasive SCC. 
6. Dysregulation of cell cycle regulatory proteins p53 and cyclin D1 and the 
cell adhesion molecule CD44 appeared to be common events taking 
place in oral SCC. 
7. The increased expression of these molecular markers in the adjacent 
non-tumoral epithelium and cases of carcinoma insitu suggested that the 
dysregulation of these proteins are early events in oral carcinogenesis. 
8. However, there was no statistically significant relationship between the 
expression of these molecular markers and histological grading. 
9. Also, in our study there was no statistical significance between 
expression of molecular markers and regional lymph node metastasis. 
10. The abnormal over expression of these molecular markers were found to 
be common even in verrucous carcinoma, a low grade variant of well 
differentiated oral SCC. 
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Figure 9: Photomicrograph of the p53 immunohistochemical staininig in 
oral SCC (Counter-stain used: Hematoxylin). The upper panel 
(Magnification: 200X) shows a brown colored positive staining of the 
malignant cells for p53. A nuclear pattern of staining is observed. In contast, 
the bottom panel (Magnification: 400x) shows a negative immunostaining for 
p53. Few scattered tumor cell nuclei exhibit very faint positivity for p53 with no 
immunoreactivity in most of the cells. 
  
Figure 10: Photomicrograph of the Cyclin D1 immunohistochemical 
staininig in oral SCC (Counter-stain used: Hematoxylin). The upper panel 
(Magnification: 200x) shows brown colored positive staining of the malignant 
cells for Cyclin D1. A nuclear pattern of staining is observed. In contrast, the 
bottom panel (Magnification: 400x) shows a negative immunostaining for 
Cyclin D1. Few scattered tumor cell nuclei exhibit very faint positivity for 
Cyclin D1 with no immunoreactivity in most of the cells. 
  
 
Figure 11: Photomicrograph of the CD44 immunohistochemical staininig 
in oral SCC (Counter-stain used-Hematoxylin; Magnification: 400x).  
The picture shows brown colored positive staining for CD44. It is restricted to 
the cell membranes of the tumor cells. 
 
 
 
  
Figure 12: Photomicrograph of p53  immunohistochemical staining in 
the adjacent non-tumoral epithelium (Magnification-200x) in 2 different 
cases. Brown colored nuclear pattern of staining is observed in both the 
basal and suprabasal layers in both the cases. 
  
 
 
Figure 13: Photomicrograph of Cyclin D1 immunohistochemical staining 
in the adjacent non-tumoral epithelium (Magnification-200x). Brown 
colored nuclear pattern of staining is observed predominantly in the suprabasal 
layers. 
 
 
  
 
 
Figure 14: Photomicrograph of CD44  immunohistochemical staining in 
the adjacent non-tumoral epithelium (Magnification-200x). Brown colored 
membranous pattern of staining is observed in the basal and suprabasal 
layers. 
           
 
Figure 15: Photomicrograph of Squamous cell carcinoma insitu. Upper 
left panel: H&E section showing full thickness dysplasia. Upper right panel: 
Immunostain for p53 - entire thickness of the epithelium shows strong 
positivity. Bottom panel: Immunostain for Cyclin D1- entire thickness of the 
epithelium shows strong positivity. 
  
Figure 16: Photomicrograph of CD44 immunostaining. Upper panel 
shows basal and suprabasal expression of CD44 in adjacent Non-Tumoral 
epithelium. In contrast lower panel shows intense full-thickness CD44 
positivity in a case of squamous cell carcinoma insitu. 
  
 
Figure 17: Photomicrograph of well differentiated OSCC arising from the 
tongue. Upper left panel: H&E section showing well keratinized tumor cells 
and few epithelial pearls. Upper right panel: Most of the tumor cells are 
negative for p53 immunostaining except a few. Bottom left panel: Nearly 1/3rd 
of the tumor cells showing moderate cyclin D1 positivity. Bottom right panel: 
Diffuse positivity for CD44 immunostaining. 
 
  
 
 
Figure 18: Photomicrograph of well differentiated OSCC- immune stain 
for p53. Counterstain used-hematoxylin. Islands of tumor cells with 
positive nuclear staining for p53. The deeply keratinized cells in the center of 
one of the island are negative for p53 staining.  
  
Figure 19: Photomicrograph of poorly differentiated SCC showing 
overexpression of all the 3 molecular markers p53, cyclin D1 and CD44. 
Upper left panel: H&E section showing markedly pleomorphic tumor cells. 
Upper right panel: Tumor cells showing strong positivity for p53 
immunostaining. Bottom left panel: Tumor cells showing strong positivity for 
Cyclin D1 immunostaining. Bottom right panel: Tumor cells showing diffuse 
moderate positivity for CD44. 
  
 
Figure 20: Photomicrograph of well differentiated oral squamous cell 
carcinoma with metastasis to regional lymph node. This picture shows 
moderate positivity for CD44 with a total score of 12. 
 
 
 
 
  
 
 
Figure 11: Photomicrograph of moderately differentiated oral squamous 
cell carcinoma with metastases to regional lymphnode. This picture 
shows diffuse strong membranous positivity for CD44 with a total CD44 score 
of 16. 
 
 
 
  
 
 
Figure 22: Photomicrograph of H & E stained section of a case of 
verrucous carcinoma (Magnification 40x). Note the intact basement 
membrane and many keratin pearls. 
 
 
 
  
 
Figure 23: Photomicrograph of P53 immunohistochemical staining in a 
case of verrucous carcinoma (Magnification=40x). Tumor shows diffuse 
nuclear positivity for p53. Intensity of the staining appears to be strong in the 
periphery of the tumor islands when compared to the staining of cells in the 
center. 
  
Figure 24: Photomicrograph of Cyclin D1 Immunohistochemical staining 
in two different cases of Verrucous carcinoma. Positive staining is seen in 
the nuclei of cells in the basal and suprabasal layer of the verrucous 
carcinoma. 
APPENDIX I: PROFORMA 
• Demographic Details 
o Name 
o Age (years) 
o Sex 
• Identification Details 
o Ward 
o IP/OP No 
• Chief complaints 
• History of presenting illness 
o History suggestive of metastatic deposit 
o Bowel and micturition habits  
o Hypertension 
o Diabetes mellitus 
• Risk Factors 
o Tobacco 
o Alcohol 
o Radiation exposure 
o Family history of OSCC 
o Immune defects 
o Occupational exposure 
• Clinical Examination 
o Tumor Characteristics 
 Site 
 Nodal status 
• Histopathological examination 
o Specimen type- Wegde biopsy/ Wide excision biopsy 
o Carcinoma type & grade 
o Adjacent epithelium 
• Immunohistochemistry score for P53,  CYCLIN D1 and CD44:  
o Extent (% positive tumor cells) 
o Intensity 
o Total score  
o Expression in adjacent epithelium 
o Intensity in adjacent epithelium 
APPENDIX II: MASTER DATA SHEET 
RISK FACTORS S.NO AG SE WAR ID NO SP HPE NO FNAC NO 
TOB ALCO HT  DM RAD FAM IMM OCC
SI CA   ADJ NO
1              46 1 S3 205970 1 1023/08 NAP 1 1 0 0 0 0 0 0 4 5 1 NAP
2                   55 1 S6 16626 1 108/09 NAP 1 1 1 0 0 0 0 0 2 3 0 0 
3                    50 2 ENT1 18775 1 119/09 F42/09 2 0 0 1 0 0 0 0 6 3 1 1
4                   55 1 S 5636 1 120/09 F21/09 1 0 0 0 0 0 0 0 3 3 2 1
5                   46 2 S6 250369 1 1369/08 NAP 2 0 0 0 0 0 0 0 2 2 0 0
6                 58 1 ENT NA 1 1601/09 NAP 1 0 0 0 0 0 0 0 8 4 1 0
7                   45 1 S NA 1 1604/09 NAP 1 1 0 0 0 0 0 0 6 4 0 0
8                    65 1 ENT1 308943 1 1608/08 NAP 1 1 0 0 0 0 0 0 8 1 1 NAP
9                    70 1 ENT2 46664 1 1943/08 NAP 1 1 0 1 0 0 0 0 5 3 0 0
10                 68 1 ENT 437276 1 2328/08 F1857/08 3 1 0 0 0 0 0 0 7 3 1 1
11                  80 2 S4 451683 1 2348/08 NAP 2 0 1 1 0 0 0 0 4 1 2 NAP
12                   40 2 S1 107338 1 2379/08 F2093/08 2 0 0 0 0 0 0 0 5 3 2 1 
13                 47 2 S5 NA 2 2525/08 F1922/08 2 0 0 0 0 0 0 0 5 2 1 1
14                    70 1 S3 484295 1 2581/08 F2051/08 3 0 0 0 0 0 0 0 4 2 1 1
15                   63 1 S2 66961 1 2717/08 NAP 1 1 1 1 0 0 0 0 4 3 1 0
16                   52 2 S 519373 1 2718/08 NAP 2 0 0 0 0 0 0 0 7 3 0 0
17                    64 2 S 25968 1 2765/08 NAP 2 0 0 0 0 0 0 0 2 2 0 0
18                    67 1 S6 450816 1 2798/08 NAP 2 1 0 1 0 0 0 0 5 2 1 0
19                    40 2 S6 537448 1 2817/08 NAP 0 0 0 0 0 0 0 0 1 5 1 NAP
20                  43 1 S 540819 1 2827/08 NAP 0 1 0 0 0 0 0 0 4 3 1 0 
21                  53 1 ENT 14902 1 644/08 F561/08 1 1 1 0 0 0 0 0 5 2 1 1
22                  60 2 S5 8838 1 66/09 NAP 2 0 1 0 0 0 0 0 1 3 1 0
23                    70 2 S3 1799 1 763/08 NAP 2 0 1 0 0 0 0 0 5 2 0 0
24                    70 2 S5 17316 2 857/08 NAP 2 0 0 0 0 0 0 0 4 5 1 NAP
25                    50 2 S 16537 1 926/08 NAP 2 0 0 0 0 0 0 0 1 5 1 NAP
 P53   CYCLIND1 CD44S.NO 
EXP          EXT IN TS TS≥4 EXPA INA EXP EXT IN  TS TS≥4 EXPA INA EXP EXT IN TS TS>4 EXPA INA
1                 1 2 3 5 1 1 4 1 2 3 5 1 3 3 1 3 3 9 1 3 3
2                    1 3 3 6 1 NAP NAP 1 2 3 5 1 NAP NAP 0 1 1 1 0 NAP NAP
3                    1 3 2 5 1 3 3 1 3 2 5 1 2 2 0 1 1 1 0 3 3
4                     1 3 3 6 1 4 4 1 1 3 4 1 4 4 1 2 2 4 0 4 4
5                    1 2 2 4 1 NAP NAP 1 1 1 2 0 NAP NAP 0 1 1 1 0 NAP NAP
6                    1 4 3 7 1 1 3 1 3 3 6 1 2 4 1 4 4 16 1 3 4
7                    1 4 3 7 1 NAP NAP 1 1 2 3 0 NAP NAP 1 2 2 4 0 NAP NAP
8                    1 4 3 7 1 3 4 1 4 3 7 1 3 4 1 4 4 16 1 3 3
9                    1 3 2 5 1 NAP NAP 1 1 2 3 0 NAP NAP 1 2 3 6 1 NAP NAP
10                    1 4 3 7 1 3 3 1 4 3 7 1 3 4 1 3 3 9 1 3 1
11                     1 4 3 7 1 3 4 1 1 3 4 1 4 4 1 2 3 6 1 4 4
12                     1 3 3 6 1 3 4 1 3 3 6 1 4 4 1 4 4 16 1 4 4
13                     1 3 3 6 1 3 3 1 2 3 5 1 2 4 0 1 1 1 0 3 3
14                     1 3 3 6 1 3 3 1 3 3 6 1 2 4 1 2 2 4 0 3 4
15                     1 2 1 3 0 1 2 1 2 2 4 1 2 3 1 3 3 9 1 3 3
16                    1 3 3 6 1 NAP NAP 1 3 3 6 1 NAP NAP 1 3 3 9 1 NAP NAP
17                    1 3 2 5 1 NAP NAP 1 2 2 4 1 NAP NAP 1 3 4 12 1 NAP NAP
18                    1 2 1 3 0 1 2 1 2 2 4 1 2 3 1 3 4 12 1 3 3
19                     1 2 3 5 1 1 3 1 2 3 5 1 2 3 1 3 4 12 1 1 4
20                     1 3 1 4 1 1 4 1 2 2 4 1 2 4 1 3 3 9 1 3 2
21                     1 3 3 6 1 3 4 1 3 2 5 1 2 4 1 4 3 12 1 3 3
22                     1 4 3 7 1 1 4 1 3 3 6 1 2 4 1 3 4 12 1 3 3
23                    1 3 3 6 1 NAP NAP 1 1 1 2 0 NAP NAP 1 2 2 4 0 NAP NAP
24                    1 3 3 6 1 1 4 1 2 2 4 1 2 4 1 3 3 9 1 3 4
25                     1 2 3 5 1 1 4 1 2 3 5 1 3 4 1 3 3 9 1 3 1
 SEX: 1-Male, 2-Female. SPECIMEN: 1-Wedge Biopsy, 2-Excision Biopsy. TOBACCO: 1-Smoking, 2-Chew, 3-Snuff. SITE: 1-Lip, 2-Alveolar 
Margin; 3-Floor Of The Mouth; 4-Buccal Mucosa; 5-Tongue; 6-Retromolar Trigone; 7-Palate; 8-Tonsil. CANCER GRADE AND TYPE: 1-Insitu;  
2-Well Differentiated; 3-Moderately Differentiated; 4-Poorly Differentiated; 5-Verrucous Carcinoma. ADJ EPI: 0-No Adjacent Epithelium Available; 
1-Normal; 2-Dysplastic. NODAL STATUS: 0-Absent; 1-Present; Nap-Not Applicable. P53 EXT IN CA: 0-No Cells; 1-<10%; 2- 10 T0 50%; 3-50 To 
90%; 4->90%. P53 INT IN CA: 0-Absent; 1-Equivocal; 2-Clearly Positive; 3-Strongly Positive. P53 EXP ADJ: 0-Absent;  
1-Present in Basal Layer; 2-Present in Suprabasal Layer; 3-Present in Both Basal and Suprabasal Layer; 4- Present in Dysplastic Epithelium. P53 
INT IN ADJ EPI: 1-Weak; 2-Mild; 3-Moderate; 4-Strong. CYD1 EXT IN CA: 0-No Cells; 1-<10%; 2- 10 T0 50%; 3-50 To 90%; 4->90%. CYD1 INT 
IN CA: 0-Absent; 1-Equivocal; 2-Clearly Positive; 3-Strongly Positive. CYD1 EXP ADJ: 0-Absent; 1-Present in Basal Layer; 2-Present in 
Suprabasal Layer; 3-Present in Both Basal and Suprabasal Layer; 4- Present in Dysplastic Epithelium. CYD1 INT IN ADJ EPI: 1-Weak; 2-Mild;  
3-Moderate; 4-Strong. CD44 INT IN CA: 1-None; 2-Mild; 3-Moderate; 4-Strong. CD44 EXP ADJ: 0-Absent; 1-Present in Basal Layer; 2-Present in 
Suprabasal Layer; 3-Present in Both Basal and Suprabasal Layer; 4- Present in Dysplastic Epithelium. CD44 INT IN ADJ EPI: 1-Weak; 2-Mild;  
3-Moderate; 4-Strong. 
APPENDIX III: DETAILS OF THE REAGENTS USED IN IMMUNOHISTOCHEMICAL 
ANALYSIS 
Name Anti p53 
Antibody 
Anti Cyclin D1 
Antibody 
Anti CD44 
Antibody*
Clone  D07;  
Mouse 
monoclonal 
Not Available; 
Rabbit  
DF1485;  
Mouse 
monoclonal 
Supplier Bio Genex Bio Genex Bio Genex 
Catalog 
Number 
Not Available  
(6ml ready to 
use antibody) 
AR4447-5R; 
(6ml ready to use 
antibody) 
AM310-5M  
(6ml ready to use 
antibody) 
Dilution - - - 
Primary 
Antibody 
Incubation 
Time/Temp 
60 min/room 
temperature 
60 min/room 
temperature 
120 min/room 
temperature 
Device Microwave Oven Microwave Oven Microwave Oven 
Buffer/pH 
value 
Tris EDTA / 9 Tris EDTA / 9 Citrate / 6 
Heat 
Temp/Time 
Medium 10 mts, 
high 10 mts 
followed by 
medium 10 mts 
Medium 10 mts, 
high 10 mts followed 
by medium 10 mts 
Medium 10 mts, 
high 10 mts 
followed by 
medium 10 mts 
Antigen 
Retrieval 
Cool 
Temp/Time 
Room temp/20 
minutes 
Room temp/20 
minutes 
Room temp/20 
minutes 
Detection 
Methods 
 Polymeric 
method 
Polymeric method Polymeric method 
Reagent DAB DAB DAB Chromogen 
Substrate Incubation 
Time/Temp 
5-8 
minutes/room 
temp 
5-8 minutes/room 
temp 
5-8 minutes/room 
temp 
Reagent Ehrlich’s 
Hematoxylin 
Ehrlich’s 
Hematoxylin 
Ehrlich’s 
Hematoxylin 
Counterstain 
Staining Time 30 seconds 30 seconds 30 seconds 
Results Staining 
Pattern  
Nucleus  Nucleus Cell membrane 
Species 
Reactivity 
Porcine Porcine Porcine 
Fixation Formalin fixed 
paraffin sections 
Formalin fixed 
paraffin sections 
Formalin fixed 
paraffin sections 
Additional 
Information 
Blocking 2-5% normal serum to reduce unspecific background 
staining;0.5-3% H2O2 to block endogenous peroxidase 
activity 
 
* - The monoclonal antibody to total CD44.
APPENDIX IV: IMMUNOHISTOCHEMISTRY PROCEDURE 
1. Sections were cut at 4 microns, taken in a coated slide & incubated at 58°C 
overnight. 
2. Deparaffinized in Xylene for 30 minutes. 
3. Immersed in absolute alcohol for 2 minutes X 2 changes. 
4. Washed in tap water for 10 minutes. 
5. Rinsed in distilled water for 5 minutes. 
6. Antigen retrieval was done using microwave sequentially- 4 times: Initially at 
medium energy for 10 minutes followed by high energy for 10 minutes and 
finally at medium energy for 5 minutes twice. 
7. Cooled to room temperature for 20 minutes. 
8. Rinsed in distilled water for 5 minutes. 
9. Washed in TBS wash buffer for 5 minutes X 2 changes. 
10. The sections were covered with peroxide block for 10 minutes. 
11. Washed in TBS wash buffer for 5 minutes X 2 changes. 
12. The sections were covered with power block for 10 minutes. 
13. The sections were drained and covered with primary antibody without washing (p53 
and Cyclin D1 for 1 hour; CD 44 for 2 hours) and kept in a moisture chamber. 
14. Washed in TBS wash buffer 5 minutes X 2 changes. 
15. The sections were covered with super enhancer for 30 minutes. 
16. Washed in TBS wash buffer for 5 minutes X 2 changes. 
17. The sections were covered with S.S label + poly HRP for 30 minutes. 
18. Washed in TBS wash buffer for 5 minutes X 2 changes. 
19. The sections were covered with chromogen (DAB + substrate buffer) for 5 to  
8 minutes. 
20. Washed in TBS wash buffer 5 minutes X 2 changes. 
21. Washed in tap water for 5 minutes. 
22. Counter stained with hematoxylin for 30 seconds. 
23. Washed in tap water for 5 min. 
24. Air dried, cleaned in Xylene and mounted with DPX mountant. 
RESULT: The development of brown color was interpreted as positive and scoring 
was done using the method mentioned previously. 
 
Note: The sections should not be allowed to dry throughout the staining procedure. 
